Work

ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps5092

Authors: Matthew Raymond Smith, Fred Saad, Maha Hussain, Cora N. Sternberg, Karim Fizazi, E. David Crawford, Karin Sayuri Yamada, Christian Kappeler, Iris Kuss, Bertrand F. Tombal

Institutions: Harvard University, Massachusetts General Hospital, Institut du cancer de Montréal, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Azienda Ospedaliera San Camillo-Forlanini, Institut Gustave Roussy, University of Colorado Health, Bayer (United States), Bayer (Germany), Cliniques Universitaires Saint-Luc

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889959771

Cites:

Cited by:

Related to: 10